OncoMatch/Clinical Trials/NCT07079423
Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis
Is NCT07079423 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Teclistamab (Tec) for al amyloidosis.
Treatment: Teclistamab (Tec) — This is a phase II study in patients with newly diagnosed Mayo stage IIIB immunoglobulin light-chain (AL) Amyloidosis to evaluate the efficacy and safety of teclistamab
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Disease stage
Required: Stage IIIB
Lab requirements
Blood counts
neutrophil ≥ 1×10E9/L, hemoglobin ≥ 8g/dL, platelet ≥ 75×10E9/L
Kidney function
estimated glomerular filtration rate ≥ 20 mL/min, not receiving renal replacement therapy
Liver function
ALT or AST ≤ 5 × ULN, total bilirubin ≤ 2 × ULN
Neutrophil <1×10E9/L, hemoglobin < 8g/dL, or platelet < 75×10E9/L. Severely compromised hepatic or renal function: ALT or AST > 5 × ULN, total bilirubin > 2 × ULN, estimated glomerular filtration rate < 20 mL/min, or receiving renal replacement therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify